Enveric Biosciences公司宣布其EB-003成为首个选择性靶向5-HT2A与5-HT1B受体的已知化合物

美股速递
May 19

Enveric Biosciences公司披露,其候选药物EB-003已成为首个已知能选择性同时作用于5-HT2A和5-HT1B受体的化合物。这一发现标志着该公司在神经精神疾病治疗领域的研发取得了重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10